Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation.

G D Hart1, C V Paya

  • 1Division of Infectious Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

Reviews in Medical Virology
|March 23, 2001
PubMed
Summary

Prophylactic therapy is recommended over pre-emptive therapy for preventing cytomegalovirus (CMV) disease in transplant patients. Prophylaxis offers broader protection against infections and may improve graft outcomes, unlike pre-emptive strategies with unproven benefits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective comparison of PCR-based vs late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allo-SCT.

Bone marrow transplantation·2010
Same author

Dr. D.a.e. Shephard.

Canadian Medical Association journal·2010
Same author

Idiopathic Hypoparathyroidism with Impaired Vitamin B(12) Absorption.

Canadian Medical Association journal·2010
Same author

Museum of the Toronto Academy of Medicine.

Canadian Medical Association journal·2010
Same author

Cancer of the ovary.

Canadian Medical Association journal·2010
Same author

Even the gods had goitre.

Canadian Medical Association journal·2010

Area of Science:

  • Transplantation Immunology
  • Virology
  • Infectious Diseases

Background:

  • Cytomegalovirus (CMV) significantly contributes to morbidity and mortality in transplant recipients.
  • Debate exists regarding the optimal strategy for preventing CMV disease: prophylactic versus pre-emptive therapy.
  • CMV's impact extends beyond disease, affecting graft outcomes and increasing superinfection risk.

Purpose of the Study:

  • To advocate for prophylactic antiviral therapy as the preferred approach for CMV prevention in transplantation.
  • To compare the efficacy, cost-effectiveness, and broader benefits of prophylactic therapy against pre-emptive strategies.
  • To address the limitations and unproven benefits of pre-emptive CMV management.

Main Methods:

  • Review of existing controlled clinical studies supporting prophylactic therapy.

Related Experiment Videos

  • Analysis of the logistical challenges and compliance issues associated with pre-emptive therapy surveillance.
  • Evaluation of evidence regarding the impact of both strategies on CMV replication, superinfections, and graft outcomes.

    • Main Results:

    • Prophylactic therapy is supported by robust evidence demonstrating efficacy and cost-effectiveness.
    • Prophylaxis provides additional benefits, including prevention of other herpesviruses, superinfections, and potentially reducing rejection.
    • Pre-emptive therapy faces challenges with intensive surveillance, patient compliance, and unproven advantages over prophylaxis.

    Conclusions:

    • Prophylactic antiviral therapy is the superior strategy for preventing CMV disease and associated complications in at-risk transplant patients.
    • The benefits of prophylactic therapy, including broader protection and potential graft improvement, outweigh those of pre-emptive approaches.
    • Effective antiviral prophylaxis is crucial for managing CMV replication and improving outcomes in the transplant population.